Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 23 of 23 publications.

Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619

Shim A, Trone D, Reynolds M, Odom D, Sherif B, Stopatschinskaja S. Patient reported outcomes (PRO) from phase 2 registrational trial of repotrectinib in patients with ROS1-positive advanced or metastatic non-small cell lung cancer (TRIDENT-1). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S421. doi: 10.1016/j.jval.2022.09.2093

Reynolds M, Odom D, Richardson D, Hollis KA, Zhan L, Mitra D, McRoy L, Bowles S. Benefits and challenges of mobile health applications in prospective studies: learnings from the Madeline Study and literature. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S71-2. doi: 10.1016/j.jval.2020.04.1183

Samuelson T, Singh IP, Katz LJ, Falvey H, Odom D, McSorley D. Effect of iStent inject trabecular micro-bypass on patient-reported outcomes for those with open-angle glaucoma and coexisting cataracts. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Rasouliyan L, Martinez D. The effect modification problem: using stratified matching adjusted indirect comparison to evade misleading interpretations of the treatment effect. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Zhou X, Eid D, Gnanasakthy A. Methods for reporting the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data in cancer clinical trials. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S226. doi: 10.1016/j.jval.2018.04.1528

Sherif B, Graham CN, Neidhardt K, Gilloteau I, O'Neill CB, McBride D, Augustin M. EQ-5D-3L utilities tariffs: differences in German and UK utilities and QALYS in patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A331.

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.

Odom D, Mladsi DM, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A122.

Novick D, Montgomery W, Aguado J, Duenas H, Haro JM. Symptomatic factors in patients with major depressive disorder (MDD): results from an observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A543.

Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Comparative effectiveness in terms of treatment discontinuation of orodispersable versus standard oral olanzapine tablets in non-adherent patients: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A766.

Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A455.

Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R. Factors associated with pain persistence in patient with depression during a 3-month follow-up period. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Amsterdam, The Netherlands. [abstract] Value Health. 2013 Nov; 16(7):A544.

Odom D, Brogan AJ, Talbird SE, Schenkel B. A network meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. [abstract] Value Health. 2013 May; 16(3):A112. doi: 10.1016/j.jval.2013.03.532

Fortuny J, Leteneux-Pantias C, Xu X, Plana E. Prevalence and incidence of pathologic myopia and retinal neovascularization in a US managed care database. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, United States. [abstract] Value Health. 2013 May; 16(3):A176.

Ascher-Svanum H, Novick D, Haro J, Aguado J, Cui Z, Anand H. Empirically-driven definitions of 'good', 'moderate' and 'poor' levels of functioning in the treatment of schizophrenia. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A287. doi: 10.1016/j.jval.2011.08.307

Carsin AE, Drummond FJ, Black A, van Leeuwen PJ, Sharp L, Murray LJ, Connolly D, Egevad L, Boniol M, Autier P, Comber H, Gavin A. Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes Control. 2010 Sep;21(9):1523-31. doi: 10.1007/s10552-010-9581-y

Pendergast K, Wolf A, Sherrill B, Zhou X, Aronne LJ, Caterson I, Finer N, Hauner H, Hill J, Van Gaal L, Coste F, Despres JP. Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. Value Health. 2010 Jun 1;13(4):402-10.

Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication nonadherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A355.

Odom D, Devercelli G, Bennett L, Peeters M, Wolf M, Amado R. Health-related quality of life (HRQOL) and colorectal cancer (CRC) symptoms in metastatic CRC: panitumumab plus best supportive care (BSC) versus bsc alone by kras tumor status. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 12, 2008. [abstract] Value Health. 2008 Nov; 11(6):487.

Zhou X, Radigue C, Allshouse AA, Gilsenan A. In Europe, how representative are overweight/obese subjects recruited via the internet? Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A326.

Zhou X, Radigue C, Maneval F, Coste F. Validity of data collected from an internet-based cohort study. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 8, 2005. Florence. [abstract] Value Health. 2005 Nov; 8(6):A76.

Irish WD, Neighbors DM, Grogg A, Lopez R, Girts T, Degen K. Performing epidemiological studies in schizophrenia: a propensity score model to predict selection of atypical antipsychotic. Poster presented at the 2002 ISPOR 7th Annual International Meeting; May 2002. Arlington, VA. [abstract] Value Health. 2002 May; 5(1):216.